期刊文献+

芜湖地区三级综合医院药学部门基本标准的现状调查

Baseline Survey of Essential Standards in Pharmacy Departments of 3Class General Hospitals in Wuhu
下载PDF
导出
摘要 目的调查分析芜湖地区三级综合医院药学部门基本标准达标情况,并提出合理化建议与解决方案。方法对芜湖地区4所三级综合医院药学部门2010年度基本标准达标情况进行问卷调查。结果调查的4所三级综合医院药学部门基本情况未完全达到卫生部《二、三级综合医院药学部门基本标准(试行)》,其中药学专业技术人员的达标问题最为突出,其次是药学部门各科室房屋面积问题。结论三级综合医院领导应重视药学部门在医院发展中的重要性,加强药学部门的标准化管理。 Objective To understand the essential standards implementation in pharmacy departments of 3 Class general hospitals in Wuhu so as to develop rational suggestions and strategies.Methods The implementation of essential standards in pharmacal departments of four 3 Class general hospitals in Wuhu,2010 was investigated by questionnaires.Results None of the investigated pharmacal departments had fully reached "the Essential Standards of Pharmacal Departments for 2 and 3 Class General Hospitals" issued by Ministry of Health,China,especially for under-standardized pharmacal professional workers and working areas.Conclusion More emphasis should be attached to the importance of pharmacal departments and standardized management of these departments needs to be strengthened.
出处 《中国药事》 CAS 2011年第12期1203-1207,共5页 Chinese Pharmaceutical Affairs
基金 安徽省临床医学技术应用项目(编号2008B057)
关键词 综合医院 药学部门 基本标准 general hospital pharmacy department essential standard
  • 相关文献

参考文献13

二级参考文献30

  • 1张宗久.加强药事与临床用药监管,促进药物合理应用[J].中国药房,2005,16(9):644-648. 被引量:102
  • 2唐强,刘海玲,刘昭前.抗高血压药物的基因组学研究进展[J].中南药学,2007,5(2):157-160. 被引量:9
  • 3Kim KA, Park PW, Lee O J, et al. Effect of CYP3A5 *3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects[J] Clin Pharmacol Tker , 2006,80(6) : 646.
  • 4Chen G, Jiang S, Mao G, et al. CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients[J] . Methods Find Exp Clin Pharmacol ,2006,28(1):19.
  • 5Kajinami K, Aka H, Polisecki E, et al. Pharmacogenomics of Statin Responsiveness[J ] . The American Journal of Cardiology,2005,96 (9A) :66.
  • 6Arazi SS, Genvigir FDV, Willrich MAV, et al. Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering - lipids response[J ] . Clinica Chimica Acta, 2008, 393(2) :119.
  • 7Deng JW, Song IS, Shin HI, et al. The effect of SLCO1B1 *15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1 * 15[J] Pharmacogent Genomics, 2008,18(5) : 424.
  • 8Zhang W, Chen BL, Ozdemir V, et al. SLCO1B1 521T> C functional genetic polymorphism and lipid lowering efficacy of multiple - dose pravastatin in Chinese coronary heart disease patients[J] . Br J Clin Pharmacol, 2007,64(3) : 346.
  • 9Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - Rationale and perspectives[J ]. Thrombosis Research, 2007,120(1) : 1.
  • 10Sanderson S, Emery J, Higgins J. CYP2C9 gene vari ants, drug dose, and bleeding risk in warfarin treated patients: A HuGEnet(tm) systematic review and meta - analysis [ J ]. Genet Med, 2005,7(2) : 98.

共引文献94

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部